×

Biotech and Pharmaceuticals Life Sciences

  • ZURICH, Sept 11- Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs. "In a best case, lampalizumab could have been a significant driver of Roche earnings growth over the next five years," Kepler Cheuvreux analyst David Evans wrote in a note.

  • PARIS, Sept 11- Sanofi and Regeneron's biotech drug dupilumab scored a hit in treating severe asthma, clinical trial data showed on Monday, raising competition in an expected multibillion-dollar market. Sanofi and Regeneron plan to submit an application to use the medicine in severe asthma to the U.S. Food and Drug Administration by the end of this year.

  • MADRID, Sept 10- A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday. The U.S. drugmaker reported three days ago it was ending the trial well ahead of schedule due to its early success in improving overall survival,...

  • The news follows Bristol-Myers Squibb Co's announcement on Wednesday that the FDA had placed similar partial clinical holds on three trials of the company's Opdivo immunotherapy in combination with multiple myeloma treatments. The FDA placed a hold on three Merck multiple myeloma combination trials in July after safety monitors reported more deaths...

  • LONDON, Sept 7- A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises to help a much broader range of patients than existing medicines like GlaxoSmithKlines Nucala. "Tezepelumab appears to be the broadest and most promising biologic for the treatment of persistent uncontrolled asthma to date," Elisabeth Bel of...

  • The FDA in July placed a hold on three Merck& Co multiple myeloma trials testing its Keytruda along with other standard medicines for the blood cancer following reports of more deaths in patients who received Keytruda than in the control arms of the studies. "The FDA determined data currently available from non-Opdivo studies indicate the risks of PD-1/PD-L1...

  • LONDON, Sept 6- A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises to help a much broader range of patients than existing medicines like GlaxoSmithKlines Nucala. Findings from a mid-stage clinical trial involving 584 patients showed on Wednesday the experimental drug tezepelumab reduced the annual rate of...

  • *Unit could fetch around $4.4 billion- analyst. FRANKFURT/ COLOGNE, Sept 5- Germany's Merck KGaA is considering selling its consumer healthcare business which has sales of $1 billion a year to help fund more research into prescription drugs and amid declines in the company's separate liquid crystal business. Fully anticipating this, we are preparing strategic...

  • LONDON, Aug 31- After last month's big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation next week when it unveils full details of two key clinical trials tackling the disease in different ways. The British drugmaker has already said the studies, known as PACIFIC and FLAURA, met their pre-defined goals but the exact...

  • Aug 30- Novartis AG on Wednesday won highly anticipated U.S. approval for the first of a new type of potent gene-modifying immunotherapy for leukemia, a $475,000 treatment that marks the start of a potential new treatment paradigm for some cancers. The approval was widely expected after an FDA advisory panel last month unanimously recommended the action.

  • The approval was widely expected after an FDA advisory panel last month unanimously recommended the action, and Novartis shares closed virtually unchanged in Swiss trading on Wednesday. Novartis announced an agreement with the U.S. Centers for Medicare and Medicaid Services under which payment for the therapy will be based on clinical outcomes achieved.

  • PRICE OF $475,000 FOR KYMRIAH GENE THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA.

  • Aug 30- The U.S. Food and Drug Administration on Wednesday gave a green light to Novartis AG's leukemia treatment, marking the first time that a highly anticipated new type of potent gene-modifying immunotherapy has gained approval in the United States. "Were entering a new frontier in medical innovation with the ability to reprogram a patients own cells to...

  • Aug 30- The U.S. Food and Drug Administration on Wednesday approved Novartis AG's keenly anticipated leukemia treatment, marking the first gene therapy approval in the United States. The drug, Kymriah, was approved for patients up to 25 years of age suffering from B-cell acute lymphoblastic leukemia, who have relapsed or failed chemotherapy.

  • Veeva Systems CEO details cloud giant's push into quality assurance

    Jim Cramer spoke with Peter Gassner, the founder and CEO of Veeva Systems, to hear about the cloud company's new target market, quality.

  • Cramer Remix: Here's how North Korea's missile could impact the stock market

    Jim Cramer broke down his thoughts on how reports that North Korea fired a missile that flew over Japan could impact the defense cohort.

  • Jim Cramer on Mad Money.

    Jim Cramer broke down his thoughts on how reports that North Korea fired a missile that flew over Japan could impact the defense cohort.

  • LONDON, Aug 23- After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneering cancer treatment. For Oxford Bio, which listed in London in 1996 after being spun out of research at the University of Oxford, it has been a long haul marked by drug setbacks and funding...

  • MUMBAI, Aug 22- India has granted Pfizer Inc a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations. The decision by India's patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in...

  • MUMBAI, Aug 22- India has granted Pfizer Inc a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations. The decision by India's patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in...